Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01839526 · ClinicalTrials.gov registry record · Phase 1
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Phase 1 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT01839526 is a Phase 1 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 39 participants.
The verdict
NCT01839526, a Phase 1 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
No investigational drug will be administered in this study for the treatment of Fabry disease. This will be a multicenter, multinational, non-treatment, cross-sectional study of young male patients with Fabry disease who have not yet initiated interventional treatment for this disease. The study will consist of a screening visit(s), a clinical investigation visit(s), and a follow-up phone contact. The objectives of the study are: * To document renal function and other Fabry disease manifestations across age in treatment-naïve, young male patients with Fabry disease. * To provide a reference group for comparison with interventional clinical trials of Fabry disease. The duration of each patient's participation in the study, inclusive of the screening visit and follow-up phone contact, will be approximately 12 weeks.
Interventions
- DRUG Iohexol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01839526
The ClinicalTrials.gov registry entry for NCT01839526 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iohexol is the first listed.
NCT01839526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01839526 about?
NCT01839526 is a clinical study titled "A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease". No investigational drug will be administered in this study for the treatment of Fabry disease. This will be a multicenter, multinational, non-treatment, cross-sectional study of young male patients with Fabry disease who have not yet initiated interventional treatment for this disease. The study wi...
What is the current status of trial NCT01839526?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2013-05. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01839526?
The interventions under investigation include: Iohexol (DRUG).
Who is sponsoring clinical trial NCT01839526?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.